{"id":7547,"date":"2026-05-18T22:22:00","date_gmt":"2026-05-18T20:22:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=e89b5090727f2e8617877b724ed89172"},"modified":"2026-05-18T22:22:00","modified_gmt":"2026-05-18T20:22:00","slug":"aspera-biomedicines-successfully-launches-second-adar1p150-crystallization-experiment-to-the-international-space-station-aboard-spacex-crs-34","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=7547","title":{"rendered":"Aspera Biomedicines Successfully Launches Second ADAR1p150 Crystallization Experiment to the International Space Station Aboard SpaceX CRS-34"},"content":{"rendered":"

\nSecond ADAR1p150 crystallization flight \u2014 Aspera\u2019s 11th ISS mission overall \u2014 now operating in microgravity to advance development of an oral Rebecsinib formulation for clinical trials across advanced cancers<\/i><\/p><\/a><\/a><\/a><\/a>

SAN DIEGO--(BUSINESS WIRE)--Aspera Biomedicines Inc., a biotechnology company developing first-in-class therapies targeting cancer stem cells, today announced that its second ADAR1p150 protein crystallization experiment has successfully launched aboard the SpaceX CRS-34 commercial resupply mission to the International Space Station (ISS).<\/p>

\nFollowing two weather-related launch scrubs earlier in the week, the Falcon 9 rocket lifted off at 6:05 PM EDT on Friday, May 15, from Cape Canaveral Space Force Station\u2019s Space Launch Complex 40 in Florida. After an approximately 36-hour transit, the Dragon spacecraft carrying Aspera\u2019s payload autonomously docked with the forward port of the station\u2019s Harmony module at 6:37 AM EDT on Sunday, May 17 \u2014 slightly ahead of the originally scheduled 7:00 AM EDT target. The crystallization experiment is now operating in microgravity.<\/p>

\nThis mission builds on Aspera\u2019s inaugural ADAR1p150 crystallization experiment, which launched aboard SpaceX Crew-12 in February 2026. Funded through NASA\u2019s In Space Production Applications (InSPA) Phase 2 award, the work uses Redwire Corporation\u2019s Pharmaceutical In-space Laboratory (PIL-BOX) technology to crystallize proteins in low Earth orbit \u2014 an environment that eliminates convection-driven crystal defects and enables structural detail impossible to obtain on Earth.<\/p>

\n\u201cThis is the second launch for Aspera\u2019s protein crystallization experiments with ADAR1, as part of a NASA InSPA Phase 2 award to further elucidate the mechanism of action of Rebecsinib and to develop an oral formulation for clinical trials in a broad array of advanced malignancies,\u201d said Dr. Catriona Jamieson, Founder and Board Member of Aspera Biomedicines. \u201cThis is a fundamentally important mission aimed at defining the mechanism of action of Aspera\u2019s ADAR1 inhibitor in addition to accelerating the development of a Rebecsinib oral formulation that could prevent cancer stem cell cloning (malignant regeneration) and cloaking from the immune system in 20 different cancers.\u201d<\/p>

\nThe Science Behind the Mission<\/p>

\nCancer stem cells drive relapse in many cancers by overexpressing a stress-response protein called ADAR1, which edits RNA to help tumors hide from the immune system and regenerate after treatment. Aspera\u2019s lead therapeutic, Rebecsinib, acts as a \u201ckill switch\u201d against ADAR1 \u2014 selectively eliminating cancer stem cells while sparing healthy ones.<\/p>

\nCrystallizing ADAR1p150 both alone and bound to Rebecsinib reveals the precise atomic geometry of the drug-target interaction. Those structural insights guide medicinal chemists toward improved formulations \u2014 including an oral version of Rebecsinib that would broaden patient access.<\/p>

\nClinical Progress<\/p>

\nRebecsinib has received FDA Investigational New Drug (IND) approval (IND #153126), and recruitment for the Phase 1 trial in patients with high-risk myelofibrosis and secondary acute myeloid leukemia is scheduled to begin in a few weeks. ADAR1 is overexpressed in more than 20 cancer types \u2014 including acute myeloid leukemia, glioblastoma, and ovarian cancer \u2014 suggesting broad therapeutic potential as Aspera advances development of oral formulations and next-generation ADAR1 inhibitors.<\/p>

\nAbout Aspera Biomedicines<\/p>

\nAspera Biomedicines is a space-accelerated biotechnology company pioneering therapies that target cancer stem cells \u2014 the root cause of cancer relapse. Founded by Dr. Catriona Jamieson, a leading cancer stem cell researcher, Aspera holds an exclusive license to Rebecsinib, a first-in-class ADAR1 inhibitor. The company has secured over $40 million in non-dilutive funding and is currently raising a $35 million Series A to accelerate clinical development. Learn more at asperabiomedicines.com<\/a>.<\/p> Contacts<\/b>

\nAra Lidstrom, Operations Manager\n(847) 636-9245\nalidstrom@asperabio.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Second ADAR1p150 crystallization flight \u2014 Aspera\u2019s 11th ISS mission overall \u2014 now operating in microgravity to advance development of an oral Rebecsinib formulation for clinical trials across advanced cancersSAN DIEGO–(BUSINESS WIRE)–Aspera Biomedic…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7547","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7547"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7547\/revisions"}],"predecessor-version":[{"id":7548,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7547\/revisions\/7548"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}